English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

as well as the lack of response in nonSCD patients in the previous report. Here we report the first in vivo evidence of using metformin in SCD patients. We demonstrate HbF increase was minimal in nonHb SS/Sβ patients, consistent with the results in previous nonSCD patients. Some HbF induction was observed in Hb SS/Sβ genotype, and combination of HU with metformin might have additional benefits. Importantly, we did not find evidence that metformin increases anemia or lactic acidosis in SCD patients. Our report is limited by the sample size and variability in the patient baseline characteristics. The compliance to metformin is difficult to assess due to the retrospective design, which may also contribute to some of the inter-individual variation in the HbF response. Our findings require substantiation in prospective clinical trials to evaluate the safety and efficacy of metformin in SCD patients.

Predicting serum ferritin levels in patients with iron overload treated with the film‐coated tablet of deferasirox during the ECLIPSE study